Immulina 400 Tablet

Immulina 400 is indicated as an adjunct therapy in patients with weakened immune systems or those prone to frequent infections, particularly in pediatric and adult populations. The tablet is administered orally, with dosage and duration tailored according to clinical condition and physician recommendation. Clinical studies have demonstrated that Pidotimod reduces the frequency and severity of infections, thereby improving patient quality of life.

It is generally well tolerated, with a low incidence of adverse effects such as gastrointestinal discomfort or allergic reactions. Immulina 400 should be used under medical supervision, especially in patients with autoimmune diseases or hypersensitivity to its components. This medication is not intended to replace standard antimicrobial therapy but serves as a supportive treatment to enhance immune competence.